MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Innoviva Company Profile (NASDAQ:INVA)

Consensus Ratings for Innoviva (NASDAQ:INVA) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $11.20 (10.13% upside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
Show:
DateFirmActionRatingPrice TargetActions
10/29/2015Robert W. BairdLower Price TargetNeutral$14.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/29/2015Cowen and CompanyLower Price TargetMarket Perform$15.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Sanford C. BernsteinReiterated RatingMarket Perform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Bank of AmericaDowngradeBuy -> Neutral$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2014Leerink SwannDowngradeOutperform -> Market Perform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2014Stifel NicolausDowngradeUnderweight$12.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Innoviva (NASDAQ:INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.08)($0.09)$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.15)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.14)($0.19)$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.44)($0.57)$4.39 million$0.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.02$0.93ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Innoviva (NASDAQ:INVA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Innoviva (NASDAQ:INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
7/30/2015quarterly$0.257.01%9/8/20159/10/20159/30/2015Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015quarterly$0.256.43%6/10/20156/12/20156/30/2015Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015quarterly$0.255.85%3/10/20153/12/20153/31/2015Tweet This Announcement  Share This Announcement on StockTwits
10/31/2014quarterly$0.256.24%11/21/201411/25/201412/23/2014Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014quarterly$0.258/26/20148/28/20149/18/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Innoviva (NASDAQ:INVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline
06/29/16 07:30 AMNoteworthy Tuesday Option Activity: VMW, INVA, KONA - Nasdaq
06/28/16 04:37 PMNoteworthy Tuesday Option Activity: VMW, INVA, KONA
06/25/16 04:21 PMStock Tracing Lower on the Week Innoviva, Inc. (:INVA) - Engelwood Daily
06/21/16 04:22 PMGlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival
06/21/16 04:22 PMGlaxo/Innoviva's Closed Triple Combination Tops Phase III
06/21/16 09:12 AMGSK FULFILS Goals, CDXC Sinks On Short Seller Report, LPTN Up On Defense Grant - Nasdaq
06/20/16 08:16 PMBRIEF-Theravance Biopharma highlights positive results from phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva - * Highlights positive top-line results from pivotal phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva
06/20/16 04:29 PMGSK triple combo study shows better lung function - MarketWatch
06/20/16 09:31 AMGlaxoSmithKline : FULFIL Study Results Closed Triple EU
06/20/16 09:31 AMGSK: FULFIL Study Meets Two Co-primary Endpoints
06/20/16 09:31 AMGSK triple combo study shows better lung function
06/20/16 09:31 AMGSK: FULFIL Study Meets Two Co-primary Endpoints - Quick Facts
06/20/16 09:31 AMGlaxo/Innoviva triple combo COPD treatment passes phase III
06/17/16 07:24 AMThe Key Numbers To Watch From Innoviva, Inc. (NASDAQ:INVA)'s Earnings - iStreetWire
06/16/16 08:55 AMThe Key Numbers To Watch From Innoviva, Inc. (NASDAQ:INVA)’s Earnings
06/11/16 04:45 PMTechnical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva - PR Newswire (press release)
06/10/16 04:31 PMINNOVIVA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive A -
06/09/16 04:50 PMTechnical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva
06/06/16 08:15 AMInvestors Traded Stocks: NetScout Systems, Inc. (NASDAQ:NTCT) , Innoviva, Inc. (NASDAQ:INVA) - Street Updates
06/02/16 07:27 AMNoteworthy Movers of Last Trading Session: Innoviva, Inc (NASDAQ:INVA) , VeriSign, Inc. (NASDAQ:VRSN) - Street Updates - Noteworthy Movers of Last Trading Session: Innoviva, Inc (NASDAQ:INVA) , VeriSign, Inc. (NASDAQ:VRSN)Street UpdatesInnoviva, Inc (NASDAQ:INVA) diminished -0.18%, closing at $11.26 after floating between $11.03 and $11.34. The company has market capitalization of $1.27B. It has twelve month low of $6.36 and twelve month high of $19.96. The recent traded volume of ...
06/01/16 03:05 PMInnoviva to Present at Jefferies 2016 Healthcare Conference on June 10 - [Marketwired] - Innoviva, Inc. today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at ...
05/25/16 08:15 AMGlaxoSmithKline hails progress with lung disease treatment - GlaxoSmithKline PLC (LON:GSK) and Innoviva Inc (NASDAQ:INVA) have taken a step forward with their potential treatment for chronic obstructive pulmonary disease (COPD). They said a study of Relvar Ellipta in an everyday clinical practice setting showed ...
05/24/16 08:00 AMSalford Lung Study Results Show COPD Patients Treated With Relvar® Ellipta® Achieve Superior Reduction in Exacerbations Compared to 'Usual Care' - Inc. For more information, please visit Innoviva's website at www.inva.com. RELVAR®, BREO®, ANORO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies. Cautionary statement regarding forward-looking statements GSK cautions investors ...
05/24/16 08:00 AMGlaxo: Relvar Ellipta Achieves Superiority Over Usual Care In Patients With COPD - GlaxoSmithKline plc (GSK.L,GSK) and Innoviva, Inc. (INVA) announced its Salford Lung Study in Chronic Obstructive Pulmonary Disease showed that Relvar Ellipta 100/25mcg achieved a superior reduction in exacerbations versus usual care, in an everyday ...
05/24/16 08:00 AMForm 8-K Innoviva, Inc. For: May 24 - Inc. For more information, please visit Innoviva’s website at www.inva.com. RELVAR®, BREO®, ANORO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
05/24/16 08:00 AMGlaxoSmithKline Says Salford Lung Study Has Positive Results - LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. ( INVA), has had positive headline results. The FTSE-100 healthcare company said the study showed that ...
05/24/16 08:00 AMGlaxoSmithKline lung study shows positive results - LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. INVA, -1.26% has had positive headline results. The FTSE-100 healthcare company said the study showed ...
05/24/16 07:45 AMGSK lung drug succeeds in big UK study, after earlier miss -
05/24/16 05:31 AMINNOVIVA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/24/16 04:59 AMSalford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care' - [Marketwired] - GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from the innovative Salford Lung Study in Chronic Obstructive Pulmonary Disease . The study showed that Relvar® Ellipta® ...
05/20/16 08:25 AMInnoviva : GSK presents new data from Breo® Ellipta® SUMMIT study in patients with COPD at ATS Conference | GSK - London-- GlaxoSmithKline (LSE/ NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand ...
05/19/16 08:09 AMTraders Actions to Focus: Innoviva Inc. (NASDAQ:INVA) , CYREN Ltd. (NASDAQ:CYRN) - Street Updates - Traders Actions to Focus: Innoviva Inc. (NASDAQ:INVA) , CYREN Ltd. (NASDAQ:CYRN)Street UpdatesOn 5/17/2016, shares of Innoviva Inc. (NASDAQ:INVA) fell -0.84% in trading session and finally closed at $10.57. The company most recent volume stood at 809.85 thousand shares as compared to its average volume of 676.66 thousand shares. Over the one ...
05/19/16 08:09 AMGlaxo (GSK), Inova Technology (INVA) Present Statistically Significant Anoro Ellipta Data at ATS 2016 - Claim your 2-week free trial to StreetInsider Premium here. GlaxoSmithKline (NYSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy ...
05/19/16 07:14 AMGlaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta -
05/18/16 03:12 PMINNOVIVA, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
05/16/16 08:08 AMTracking Seth Klarman's Baupost Group Holdings - Q1 2016 Update - The stock currently trades at $18.20. Note: Klarman controls ~12% of the business. Innoviva Inc. (NASDAQ:INVA) previously Theravance: INVA is a 3.60% of the US long portfolio stake. It is a very long-term position that has been in the portfolio since 2008.
05/13/16 07:51 AMTake a look at Price Fluctuations: Innoviva, Inc. (NASDAQ:INVA) , SK Telecom Co., Ltd. (NYSE:SKM) - Street Updates - Take a look at Price Fluctuations: Innoviva, Inc. (NASDAQ:INVA) , SK Telecom Co., Ltd. (NYSE:SKM)Street UpdatesTake a look at Price Fluctuations: Innoviva, Inc. (NASDAQ:INVA) , SK Telecom Co., Ltd. (NYSE:SKM) - The following two tabs change content below.BioLatest Posts admin Latest posts by admin (see all) Latest Analysts Score of Stocks: Intel Corporation ...
05/13/16 07:51 AMInnoviva Breaks Below 200-Day Moving Average - Notable for INVA - Nasdaq - NasdaqInnoviva Breaks Below 200-Day Moving Average - Notable for INVANasdaqIn trading on Thursday, shares of Innoviva Inc (Symbol: INVA) crossed below their 200 day moving average of $11.03, changing hands as low as $10.69 per share. Innoviva Inc shares are currently trading off about 3.4% on the day. The chart below shows ...and more »
05/13/16 07:51 AMInnoviva Breaks Below 200-Day Moving Average - Notable for INVA - In trading on Thursday, shares of Innoviva Inc (Symbol: INVA) crossed below their 200 day moving average of $11.03, changing hands as low as $10.69 per share. Innoviva Inc shares are currently trading off about 3.4% on the day. The chart below shows the ...
05/12/16 12:04 PMINNOVIVA, INC. Financials -
05/09/16 09:26 AMTheravance Gets FDA Nod on Vibativ -
05/07/16 04:55 PMStock Latest Update: Universal Display Corporation (NASDAQ:OLED) , Innoviva Inc (NASDAQ:INVA) - Is stories - Is storiesStock Latest Update: Universal Display Corporation (NASDAQ:OLED) , Innoviva Inc (NASDAQ:INVA)Is storiesIn most recently trading session on 5/6/2016, Innoviva Inc (NASDAQ:INVA) climbed +2.52% while traded on 631.2 thousand shares versus it's an average volume of 687.27 thousand shares. The company recorded the last trade with the price of $11.82.and more »
05/05/16 03:07 PMINNOVIVA, INC. Files SEC form 10-Q, Quarterly Report -
05/05/16 07:47 AMInnoviva Becomes Oversold (INVA) - Nasdaq - Innoviva Becomes Oversold (INVA)NasdaqIn trading on Wednesday, shares of Innoviva Inc (Symbol: INVA) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $11.45 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 43.7.and more »
05/05/16 07:47 AMInvestors Trading Alert: Rubicon Technology, Inc. (NASDAQ:RBCN) , Innoviva, Inc. (NASDAQ:INVA) - Street Updates - Investors Trading Alert: Rubicon Technology, Inc. (NASDAQ:RBCN) , Innoviva, Inc. (NASDAQ:INVA)Street UpdatesOn 5/4/2016, shares of Rubicon Technology, Inc. (NASDAQ:RBCN) fell -5.446% in trading session and finally closed at $0.625. The company most recent volume stood at 167.8 thousand shares as compared to its average volume of 166.52 thousand shares.and more »
05/04/16 06:02 PMBRIEF-Theravance Biopharma announces closing of public offering of ordinary shares - * Announces closing of public offering of its ordinary shares Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
05/04/16 04:58 PMInnoviva Becomes Oversold (INVA) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Innoviva Inc (Symbol: INVA) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $11.45 per share.
05/03/16 05:56 PMInnoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11 - [Marketwired] - Innoviva, Inc. today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May ...
05/03/16 11:11 AMInnoviva, Inc. :INVA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/02/16 04:55 PMCould Innoviva Inc See a Reversal After This Very Weak Session? - B.O.D.Y Confidential - Could Innoviva Inc See a Reversal After This Very Weak Session?B.O.D.Y ConfidentialThe stock of Innoviva Inc (NASDAQ:INVA) is a huge mover today! The stock decreased 2.67% or $0.33 during the last trading session, hitting $12.01. About 1.27M shares traded hands or 75.22% up from the average. Innoviva Inc (NASDAQ:INVA) has risen ...and more »
About Innoviva

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is an asset management company that is focused on the development, commercialization and financial management of bio-pharmaceuticals. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI), with the intention of providing capital returns to stockholders. Its RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2 agonist (LABA), and fluticasone furoate (FF), an inhaled corticosteroid (FF/VI) delivered through the ELLIPTA dry powder inhaler. Its ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), which is used for the treatment of chronic obstructive pulmonary diseases (COPD).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INVA
  • CUSIP: 88338T10
Key Metrics:
  • Previous Close: $9.91
  • 50 Day Moving Average: $11.06
  • 200 Day Moving Average: $11.32
  • P/E Ratio: N/A
  • P/E Growth: -0.12
  • Market Cap: $1.15B
  • Current Quarter EPS Consensus Estimate: $0.54 EPS
Additional Links:
Innoviva (NASDAQ:INVA) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha